Panther Therapeutics

Panther Therapeutics company information, Employees & Contact Information

PanTher Therapeutics is a clinical-stage oncology company offering transformational localized treatment of cancer. This is accomplished through its proprietary Sagittari™ platform which enables continuous, high-dose treatment of potent oncology agents exclusively at the site of a tumor. The Sagittari™ treatment platform is a revolutionary solution for local administration of therapeutic agents. This foundational technology was invented at the Massachusetts Institute of Technology by PanTher’s founder and CEO. Sagittari is a polymer-based system that allows therapeutic agents to be formulated in a wide range of dosage forms that can be administered to the surface of a cancerous organ or implanted directly into a tumor. The drug product is designed to continuously deliver drug for weeks or months at a desired dose level, without unwanted dose-limiting side effects. PanTher’s lead clinical candidate, PTM-101, has successfully been evaluated in a Phase 1 clinical trial in treatment naïve localized non-metastatic pancreatic cancer patients. PanTher is exploring opportunities to utilize its platform technology in additional solid tumor indications.

Company Details

Employees
16
Founded
-
Address
7000 Bee Caves Rd, Ste. 300,united States
Email
in****@****rtx.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Austin, Texas
Looking for a particular Panther Therapeutics employee's phone or email?

Panther Therapeutics Questions

News

PanTher Completes First Cohort in Pancreatic Cancer Phase 1b Trial Ahead of Expectations - Business Wire

PanTher Completes First Cohort in Pancreatic Cancer Phase 1b Trial Ahead of Expectations Business Wire

MassCONNECT Celebrates a Successful 2015! - Massachusetts Biotechnology Council

MassCONNECT Celebrates a Successful 2015! Massachusetts Biotechnology Council

PanTher Initiates Phase 1b Clinical Trial of Absorbable, Long-Lasting, High-Dose Chemotherapy Patch for Pancreatic Cancer - Business Wire

PanTher Initiates Phase 1b Clinical Trial of Absorbable, Long-Lasting, High-Dose Chemotherapy Patch for Pancreatic Cancer Business Wire

PanTher Therapeutics Receives FDA Clearance of IND Application for Phase 1b Study of PTM-101 for the Localized Treatment of Pancreatic Cancer - Business Wire

PanTher Therapeutics Receives FDA Clearance of IND Application for Phase 1b Study of PTM-101 for the Localized Treatment of Pancreatic Cancer Business Wire

Top Panther Therapeutics Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant